Oncology Specialists, S.C.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Oncology Specialists, S.C. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Oncology Specialists, S.C.: 10 sponsored US clinical trials, none currently recruiting.

Oncology Specialists, S.C. sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Non-Hodgkin, with 1 trials.

Top-decile sponsor footprint

Oncology Specialists, S.C. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

TERMINATED Phase 2

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

NCT01078922
COMPLETED Phase 2

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

NCT00919035
COMPLETED Phase 2

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

NCT00654186
COMPLETED Phase 1

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

NCT00424385
COMPLETED Phase 1

Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

NCT00414388
TERMINATED Phase 2

VELCADE,Rituximab,Cyclophosphamide and Decadron

NCT00413959
COMPLETED Phase 2

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

NCT00274287
COMPLETED Phase 2

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

NCT00272038
COMPLETED Phase 1

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

NCT00156013
TERMINATED Phase 2

Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer

NCT00145418

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 7

Therapeutic Areas

Lymphoma, Non-Hodgkin 1
Prostate Cancer 1
Lymphoma, B-Cell 1

How the Oncology Specialists, S.C. early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Lymphoma, Non-Hodgkin (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Oncology Specialists, S.C.: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Oncology Specialists, S.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Oncology Specialists, S.C.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Oncology Specialists, S.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Oncology Specialists, S.C. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Oncology Specialists, S.C. page

10 registered trials is a research-attention snapshot, not an endorsement of Oncology Specialists, S.C. or any single study.

  • None of Oncology Specialists, S.C.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Lymphoma, Non-Hodgkin is the condition Oncology Specialists, S.C. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Non-Hodgkin trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Oncology Specialists, S.C. pipeline card: 10 registered trials from official public datasets.Report a data error.